The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor ... and immediately raised concerns from analysts and investors worried about direct competition in the ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy ... Transgender issues are a strength ...

Zepbound's prescription growth has surged ahead of Novo Nordisk's rival GLP-1 weight-loss drug Wegovy in recent months after struggles with supply issues ... said the CVS coverage decision will ...

But employers and unions will ultimately determine how much of those savings on Wegovy get shared with members, CVS said ... the weight loss drug market and concerns that Zepbound's sales ...